Sana Biotechnology (NASDAQ:SANA) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Sana Biotechnology (NASDAQ:SANA) in a research note published on Wednesday,Benzinga reports. They currently have a $8.00 price objective on the stock.

A number of other analysts have also weighed in on the stock. Citigroup upped their target price on shares of Sana Biotechnology from $8.00 to $15.00 and gave the stock a “buy” rating in a report on Friday, August 9th. JMP Securities cut shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th.

Sana Biotechnology Price Performance

Sana Biotechnology stock opened at $2.55 on Wednesday. The firm has a market capitalization of $569.34 million, a P/E ratio of -1.82 and a beta of 1.44. Sana Biotechnology has a one year low of $2.29 and a one year high of $12.00. The business has a fifty day moving average price of $3.61 and a 200-day moving average price of $5.21.

Sana Biotechnology (NASDAQ:SANA) last issued its earnings results on Friday, November 8th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.01. Sell-side analysts expect that Sana Biotechnology will post -1.16 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Sana Biotechnology news, Director Richard Mulligan sold 150,000 shares of the firm’s stock in a transaction dated Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total transaction of $612,000.00. Following the sale, the director now owns 2,848,121 shares in the company, valued at $11,620,333.68. This trade represents a 5.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 31.10% of the company’s stock.

Hedge Funds Weigh In On Sana Biotechnology

Several institutional investors have recently modified their holdings of SANA. FMR LLC boosted its stake in Sana Biotechnology by 16.3% in the third quarter. FMR LLC now owns 31,609,175 shares of the company’s stock worth $131,494,000 after buying an additional 4,438,949 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Sana Biotechnology by 24.1% in the 1st quarter. Vanguard Group Inc. now owns 12,155,173 shares of the company’s stock worth $121,552,000 after acquiring an additional 2,358,089 shares during the last quarter. State Street Corp boosted its stake in shares of Sana Biotechnology by 4.2% in the 3rd quarter. State Street Corp now owns 6,627,320 shares of the company’s stock valued at $27,570,000 after purchasing an additional 269,274 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Sana Biotechnology by 2.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,695,459 shares of the company’s stock valued at $36,956,000 after purchasing an additional 101,434 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in Sana Biotechnology by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 3,166,480 shares of the company’s stock worth $13,175,000 after purchasing an additional 276,055 shares during the period. 88.23% of the stock is currently owned by institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.